|
10 45
|
INTEGRATING PRIVATE- AND PUBLIC-SECTOR SURVEILLANCE: WHAT IS HAPPENING AND WHAT IS NEEDED
Rosamund Williams, WHO
Renu Gupta, Bristol-Myers Squibb
Laurence McCarthy, MRL Pharmaceutical Services
|
|
11:30
|
SURVEILLANCE AND THE LABORATORY: WHAT ARE THE ISSUES?
Fred Tenover, CDC
|
|
11:45
|
HOW CAN THE SCIENCE HELP?
Implications of Mapping the Genome
Craig Venter, Institute for Genomic Research
|
|
|
Molecular Detection of Genes Associated with Antimicrobial Resistance
David Relman, Stanford University
|
|
12:30
|
LUNCH
|
|
1:30
|
HOW CAN THE SCIENCE HELP? (continued)
High-Density Oligonucleotide Arrays
Tom Gingeras, Affymetrix
|
|
|
Applications of Genomics/Bioinformatics to Development of Anti-Infectives
George Miller, Schering-Plough Research Institute
|
|
|
A Role for New Therapeutic Approaches in Combating Antimicrobial Resistance
Mich Hein, EPIcyte
|
|
|
Applications of Field Surveillance (U.S. and International)
Thomas Quinn, Johns Hopkins University
|
|
2:30
|
SOURCES OF RESISTANCE AND NOTIONS OF RESPONSE
Stuart Levy, Tufts University
|
|
2:45
|
ISSUES OF JUDICIOUS ANTIBIOTIC USE
Mitchell Cohen, CDC
|
|
3:00
|
ISSUES IN AND STRATEGIES FOR CLINICAL USE OF ANTIMICROBIALS
Michael Marcy, Kaiser Permanente
|